Cutaneous Manifestations Associated With Immune Checkpoint Inhibitors
February 2023
in “
Frontiers in immunology
”
immune checkpoint inhibitors cutaneous immune-related adverse events rashes pruritus vitiligo-like depigmentation bullous diseases alopecia T cell activation proinflammatory cytokines corticosteroids immunomodulators ICIs skin reactions itching skin depigmentation blistering diseases hair loss steroids
Studysummary This review discusses the range of cutaneous immune-related adverse events induced by immune checkpoint inhibitors and the proposed mechanisms underlying these skin reactions, but reports no new clinical results. Our plain-language summary of this paper — not a Tressless recommendation.
Immune checkpoint inhibitors (ICIs) used in cancer therapy can cause various cutaneous immune-related adverse events (irAEs), such as rashes, pruritus, vitiligo-like depigmentation, bullous diseases, and alopecia. These skin reactions, which occur in 30-60% of patients depending on the ICI, are linked to better tumor responses and improved survival rates, particularly in metastatic melanoma. The exact mechanisms are unclear but may involve T cell activation and proinflammatory cytokines. Effective management of these dermatologic toxicities, including the use of corticosteroids and immunomodulators, is crucial for patient comfort and continued treatment efficacy.
